Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
Rhea-AI Summary
INOVIO (NASDAQ: INO) reported that partner ApolloBio announced positive topline results from a pivotal Phase 3 trial of VGX-3100 in cervical dysplasia patients. The study met its predefined primary efficacy endpoint and showed an overall favorable safety and tolerability profile, supporting a planned regulatory submission in China.
Under the ApolloBio agreement, INOVIO may receive up to $20 million in regulatory milestones, net of taxes, plus tiered royalties on annual net sales if VGX-3100 is approved and marketed in specified territories.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Phase 3 VGX-3100 trial met predefined primary efficacy endpoint
- Trial reported overall favorable safety and tolerability profile
- Results planned to support regulatory submission for VGX-3100 in China
- INOVIO eligible for up to $20 million in approval-related milestones
- Potential future tiered royalties on VGX-3100 annual net sales if approved
Negative
- Regulatory submission and approval for VGX-3100 in China still pending
- Milestone and royalty payments depend on achieving specified approval and sales milestones
News Market Reaction – INO
On the day this news was published, INO gained 1.50%, reflecting a mild positive market reaction. Argus tracked a peak move of +13.0% during that session. Argus tracked a trough of -4.3% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $118.88M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Earnings and pipeline | Positive | +1.5% | Q1 2026 results, cash runway into Q1 2027, INO-3107 BLA update. |
| May 08 | Conference participation | Positive | +6.6% | Scientific conference presentations on gene therapy and INO-3107 data. |
| May 01 | Earnings date notice | Neutral | +3.6% | Scheduling and announcing upcoming Q1 2026 earnings call. |
| Apr 02 | Financing priced | Negative | -35.1% | Pricing of $17.5M equity offering with accompanying warrants. |
| Apr 01 | Financing proposed | Negative | -35.1% | Announcement of proposed underwritten equity and warrant offering. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Financing announcements drew sharp negative reactions, while operational and event-driven updates (earnings, conferences) saw modest positive moves.
Over the last two months, INOVIO combined dilution and pipeline progress. Two April public offering announcements led to steep ~-35% one-day reactions, highlighting sensitivity to equity financing. In May, an earnings date notice, Q1 2026 results, and conference participation each coincided with modest positive moves, suggesting investors have responded constructively to operational and scientific updates. Today’s positive Phase 3 topline data from the ApolloBio partnership fits that pattern of clinical and partnership milestones supporting sentiment despite prior dilution.
Key Terms
dna immunotherapy medical
dna medicine medical
human papillomavirus (hpv) medical
cervical dysplasia medical
phase 3 medical
regulatory submission regulatory
topline results technical
royalty payments financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Results provide important clinical evidence to support ApolloBio's future regulatory submission in
China of VGX-3100, INOVIO's DNA immunotherapy candidate - ApolloBio's new clinical results further highlight the potential of INOVIO's DNA medicine platform to treat diseases caused by infection with various strains of the human papillomavirus (HPV), eliminating or reducing the need for surgical interventions
"We believe these positive topline results for VGX-3100 reflect both the potential of our DNA medicine platform in HPV-related diseases and the power of partnerships to advance innovative DNA immunotherapies," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "We look forward to these data being presented at upcoming international medical conferences and published in peer-reviewed publications. We also anticipate future updates from ApolloBio as they work towards filing for potential regulatory approval of VGX-3100 in
According to the terms of the ApolloBio Agreement, INOVIO is entitled to receive up to an aggregate of
About VGX-3100
VGX-3100 is an innovative therapeutic DNA vaccine developed for diseases associated with high-risk human papillomavirus (HPV) types 16 and 18. VGX-3100 is designed to elicit an antigen-specific, CD8+ T cell response to clear persistent HPV 16/18 infection, thereby promoting lesion regression and viral clearance.
INOVIO licensed VGX-3100 to ApolloBio in 2018 for
About ApolloBio's Phase 3 Trial with VGX-3100
The study, sponsored by ApolloBio, is a multicenter, prospective, randomized, double-blind, placebo-controlled Phase 3 pivotal registrational clinical trial for the treatment of HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL), or cervical dysplasia. The primary endpoint was the composite response rate at Week 36, defined as histopathologic regression of cervical disease to low-grade lesion (CIN1) or normal histology, together with clearance of HPV-16 and/or HPV-18 infection. The study was led by Cancer Hospital, Chinese Academy of Medical Sciences, with Professor Lingying Wu serving as the leading principal investigator. A total of 22 top-tier tertiary hospitals across
ApolloBio announced that the trial successfully met its predefined primary efficacy endpoint and demonstrated an overall favorable safety and tolerability profile, with no new significant safety risk signals observed. The positive outcome of this study provides important clinical evidence to support ApolloBio's future regulatory submission of VGX-3100 in
About HPV, Cervical Cancer, and Cervical Dysplasia
HPV is the most common sexually transmitted infection and is the main cause of cervical cancer, which is the fourth most common cancer in women globally with around 660,000 new cases and 350,000 deaths in 2022. Two types of HPV (HPV 16 and HPV 18) collectively cause about 70 percent of cervical cancer cases worldwide. High-grade cervical dysplasia is also caused by persistent HPV infection and is a precancerous condition that can progress to cervical cancer if left untreated. Currently there are no US-approved therapeutic treatments for persistent HPV infection or cervical dysplasia.
About INOVIO's DNA Medicines Platform
INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
About ApolloBio
ApolloBio Corp. is a leading Chinese biomedical company committed to research and development of innovative new medicines, accessing such new medicines through in-licensing, and additionally providing medical services. ApolloBio Corp. is focused on pharmaceutical products with significant market potential in
Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business, including the potential of VGX-3100 for the treatment of cervical dysplasia, including the reproducibility of the clinical trial results in any future trials and the success of any future regulatory submission; the potential of INOVIO's DNA medicine platform in HPV-related diseases; our ability to establish and maintain development partnerships; and our expectations regarding future milestone or royalty payments. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
INOVIO Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/positive-topline-results-from-a-phase-3-trial-for-vgx-3100-in-cervical-dysplasia-patients-announced-by-apollobio-inovios-partner-in-china-302779378.html
SOURCE INOVIO Pharmaceuticals, Inc.